Severity of Nonalcoholic Fatty Liver Disease and Progression to Cirrhosis Are Associated With Atherogenic Lipoprotein Profile-Reference-Cited by-同舟云学术

Severity of Nonalcoholic Fatty Liver Disease and Progression to Cirrhosis Are Associated With Atherogenic Lipoprotein Profile

Published:2015-05 Issue:5 Volume:13 Page:1000-1008.e3
ISSN:1542-3565
Container-title:Clinical Gastroenterology and Hepatology
language:en
Short-container-title:Clinical Gastroenterology and Hepatology

Author:

Siddiqui Mohammad S.,Fuchs Michael,Idowu Michael O.,Luketic Velimir A.,Boyett Sherry,Sargeant Carol,Stravitz Richard T.,Puri Puneet,Matherly Scott,Sterling Richard K.,Contos Melissa,Sanyal Arun J.

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference30 articles.

1. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults;Vernon;Hepatology,2011

2. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association;Chalasani;Hepatology,2012

3. The natural history of nonalcoholic fatty liver disease: a population-based cohort study;Adams;Gastroenterology,2005

4. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease;Targher;N Engl J Med,2010

5. Biomarkers for the prediction of type 2 diabetes and cardiovascular disease;Herder;Clin Pharmacol Ther,2011

Cited by 173 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases;Frontiers in Cell and Developmental Biology;2024-07-16

2. Correlation between controlled attenuation parameter values with SYNTAX score in patients with significant coronary artery disease;Scientific Reports;2024-07-04

3. Integrating behavioral interventions into a holistic approach to metabolic dysfunction-associated steatotic liver disease;Expert Review of Gastroenterology & Hepatology;2024-07-02

4. PNPLA3 is a triglyceride lipase that mobilizes polyunsaturated fatty acids to facilitate hepatic secretion of large-sized very low-density lipoprotein;Nature Communications;2024-06-06

5. Effects of empagliflozin on liver fat in patients with metabolic dysfunction–associated steatotic liver disease without diabetes mellitus: A randomized, double-blind, placebo-controlled trial;Hepatology;2024-03-27